Ovid Therapeutics Inc (OVID)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jeremy M. Levin
Employees:
60
1460 BROADWAY, SUITE 15044, NEW YORK, NY 10036
212-776-4381

Ovid Therapeutics Inc. develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome. OV329, a GABA aminotransferase inhibitor, and OV350, a small molecule for treating epilepsies.

Data derived from most recent annual or quarterly report
Market Cap 270.687 Million Shares Outstanding70.492 Million Avg 30-day Volume 128.81 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.19
Price to Revenue1472.0987 Debt to Equity0.0 EBITDA-49.761 Million
Price to Book Value1.5037 Operating Margin-43850.1562 Enterprise Value58.164 Million
Current Ratio17.783 EPS Growth0.27 Quick Ratio17.515
1 Yr BETA 0.7078 52-week High/Low 3.89 / 1.41 Profit Margin-41619.1919
Operating Cash Flow Growth24.2423 Altman Z-Score2.2948 Free Cash Flow to Firm -39.623 Million
Earnings Report2023-08-08
View SEC Filings from OVID instead.

View recent insider trading info

Ovid Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding OVID (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OVID

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-02-27 by TARDIO JASON
  • 4: filed on 2023-02-27 by RONA JEFFREY A
  • 4: filed on 2023-02-27 by POOLE ROBERT MICHAEL
  • 4: filed on 2023-02-27 by PERONE THOMAS MICHAEL
  • 4: filed on 2023-02-27 by LEVIN JEREMY M
  • 4: filed on 2023-02-27 by FRIEDMAN BART
  • 4: filed on 2023-02-27 by FITZGERALD KEVIN JOSEPH
  • 4: filed on 2023-02-27 by DUNCAN BARBARA GAYLE
  • 4: filed on 2023-02-27 by BERNSTEIN KAREN
  • 4: filed on 2022-09-14 by TARDIO JASON

    • Events (8k)

  • 8-K: filed on 2023-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-01:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-27:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-13:
    Item 2.02: Results of Operations and Financial Condition
  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-10:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-11:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LEVIN JEREMY M CEO

    • Officer
    • Director
    • 10% Owner
    		 0 2023-02-23 1

    RONA JEFFREY A CBFO

    • Officer
    		 0 2023-02-23 1

    DUNCAN BARBARA GAYLE

    • Director
    		 0 2023-02-23 1

    FRIEDMAN BART

    • Director
    		 0 2023-02-23 1

    BERNSTEIN KAREN

    • Director
    		 0 2023-02-23 1

    PERONE THOMAS MICHAEL GENERAL COUNSEL, SECRETARY

    • Officer
    		 0 2023-02-23 1

    TARDIO JASON CHIEF OPERATING OFFICER

    • Officer
    		 0 2023-02-23 2

    POOLE ROBERT MICHAEL

    • Director
    		 0 2023-02-23 1

    FITZGERALD KEVIN JOSEPH

    • Director
    		 0 2023-02-23 1

    TAKEDA PHARMACEUTICAL CO LTD

    TAKEDA PHARMACEUTICALS U.S.A., INC.

    • 10% Owner
    		 7,531,996 2022-07-01 1

    RAKHIT AMIT PRESIDENT AND CMO

    • Officer
    		 817,806 2021-07-14 0

    WILLIAMS DOUGLAS E

    • Director
    		 1,750 2021-05-17 0

    DALY TIMOTHY EVP,FINANCE & CORP. CONTROLLER

    • Officer
    		 0 2020-12-17 0

    HAASNER DIRK SVP, GLOBAL REGULATORY AFFAIRS

    • Officer
    		 0 2020-12-17 0

    TAKEDA PHARMACEUTICAL CO LTD

    MILLENNIUM PHARMACEUTICALS INC

    • 10% Owner
    		 5,750,000 2019-10-08 1

    DURING MATTHEW PRESIDENT AND CSO

    • Officer
    • Director
    • 10% Owner
    		 0 2019-02-24 0

    WARD ANA SVP AND GENERAL COUNSEL

    • Officer
    		 0 2019-02-24 0

    WERBER YARON CBO, CFO, SEC. AND TREAS.

    • Officer
    		 0 2018-01-19 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    OVID THERAPEUTICS INC OVID 2023-06-06 22:15:03 UTC 4.4087 0.6613 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 21:45:05 UTC 4.4087 0.6613 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 21:15:04 UTC 4.4087 0.6613 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 20:45:04 UTC 4.4087 0.6613 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 20:15:04 UTC 4.4087 0.6613 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 19:45:04 UTC 4.4087 0.6613 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 19:15:03 UTC 4.4087 0.6613 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 18:45:04 UTC 4.4087 0.6613 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 18:15:04 UTC 4.4087 0.6613 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 17:45:04 UTC 4.4087 0.6613 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 17:15:04 UTC 4.4087 0.6613 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 16:45:04 UTC 4.4096 0.6504 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 16:15:03 UTC 4.4096 0.6504 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 15:45:04 UTC 4.4096 0.6504 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 15:15:04 UTC 4.4096 0.6504 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 14:45:04 UTC 4.4015 0.6585 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 14:15:03 UTC 4.4015 0.6585 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 13:45:03 UTC 4.4015 0.6585 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 13:15:03 UTC 4.4015 0.6585 350000
    OVID THERAPEUTICS INC OVID 2023-06-06 12:45:05 UTC 4.4015 0.6585 350000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund OVID -1800.0 shares, $-4644.0 2023-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments